IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML

Oncoimmunology
Belen Lopez-MillanPablo Menendez

Abstract

Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the BM stroma is a major mechanism underlying therapy resistance in AML. Lenalidomide and pomalidomide, a new generation immunomodulatory drugs (IMiDs), possess pleiotropic anti-leukemic properties including potent immune-modulating effects and are commonly used in hematological malignances associated with intrinsic dysfunctional BM such as myelodysplastic syndromes and multiple myeloma. Whether IMiDs may improve the efficacy of current standard treatment in AML remains understudied. Here, we have exploited in vitro and in vivo preclinical AML models to analyze whether IMiDs potentiate the efficacy of AraC/Idarubicin-based standard AML chemotherapy by interfering with the BM stroma-mediated chemoresistance. We report that IMiDs do not exert cytotoxic effects on either non-del5q/5q- AML cells nor BM-MSCs, but they enhance the immunomodulatory properties of BM-MSCs. When combined with AraC/Idarubicin, IMiDs fail to circumvent BM stroma-mediated resistance of non-del5q/5q- AML cells in vitro and in vivo but induce...Continue Reading

References

Jul 14, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A ScheyA G Dalgleish
Mar 17, 2010·Nature Medicine·Douglas W McMillinConstantine S Mitsiades
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William BlumJohn C Byrd
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marina Y Konopleva, Craig T Jordan
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
Jan 18, 2012·Current Opinion in Hematology·Alan K Burnett
Jan 16, 2013·Expert Opinion on Investigational Drugs·Yiming Chen, Gautam Borthakur
Mar 2, 2013·Nature Reviews. Drug Discovery·Douglas W McMillinConstantine S Mitsiades
Oct 29, 2013·Nature Chemical Biology·Kimberly A HartwellTodd R Golub
Nov 2, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexandra MorosGaël Roué
Aug 16, 2015·American Journal of Clinical Pathology·Anna Porwit, Marie C Béné
Sep 1, 2015·Oncotarget·María Dolores Cuenca-LópezAlberto Ocaña
Oct 12, 2015·Critical Reviews in Oncology/hematology·Rossana MaffeiRoberto Marasca
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Jan 26, 2016·Critical Reviews in Oncology/hematology·T JelinekR Hajek

❮ Previous
Next ❯

Citations

Oct 6, 2020·Frontiers in Oncology·Daniel CancillaJohn F DiPersio
Sep 2, 2021·Blood Advances·Rafael Díaz de la GuardiaPablo Menéndez

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE106748

Methods Mentioned

BETA
FACS
flow cytometry
MDS
flow-cytometry
xenograft

Software Mentioned

FACSDiva
IPA
Gorilla

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.